Condition

Metastatic Colorectal Cancer clinical trials and research

• 66Clinical trials
• 19NIH research projects
• 1New in 30 days
• 41Countries

Newest Metastatic Colorectal Cancer clinical trials

All recruiting trials (66)

• Becotatug Vedotin plus Pucotenlimab for EGFR-positive metastatic colorectal cancer

  This study tests whether combining becotatug vedotin with pucotenlimab can shrink tumors in adults with colorectal cancer that has returned or spread after at least two prior treatments and whose tumors express EGFR.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07884188

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

• Immunotherapy plus Simvastatin and Targeted Therapy with Chemotherapy for Advanced Colorectal Cancer

  This trial tests whether adding immune therapy (adbelimumab? actually Adebrelimab) with simvastatin and targeted therapy to standard chemotherapy helps people with metastatic colorectal cancer that is MSI-H/dMMR or MSS/pMMR depending on combination.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu and 1 other locations · NCT07718490

• Fruquintinib treatment in adults with metastatic colorectal cancer in Poland

  This study looks at whether taking fruquintinib by mouth after prior therapies helps adults with metastatic colorectal cancer in Poland live longer before the cancer progresses and overall survival, while also considering quality of life.

  Recruiting at 3 sites Takeda · Poznan, Greater Poland Voivodeship and 9 other locations · NCT07623174

• Understanding why BRAF V600E colorectal cancer stops responding to targeted therapy

  This study tests why metastatic colorectal cancer with a BRAF V600E mutation stops responding to encorafenib and cetuximab, by collecting tissue, blood, and stool samples over time.

  Recruiting at 13 sites Swiss Cancer Institute · Aarau and 12 other locations · NCT07617610

• Second-line combination treatment for MSS metastatic colorectal cancer

  This trial will try folinic acid plus continuous 5-FU with liposomal irinotecan, sometimes combined with cetuximab or bevacizumab, as a second-line option for adults with MSS metastatic colorectal cancer who progressed on or cannot tolerate oxaliplatin-based therapy.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07559760

• Comparing Precem-TcT (with or without bevacizumab) versus trifluridine/tipiracil plus bevacizumab for people with previously treated metastatic colorectal cancer

  This trial will see if Precem-TcT, alone or with bevacizumab, helps people with metastatic colorectal cancer who have already received standard chemotherapy, compared with trifluridine/tipiracil plus bevacizumab.

  Recruiting at 116 sites Phase 3 EMD Serono · San Francisco, California and 115 other locations · NCT07549412

• RPH-030 versus Vectibix with FOLFIRI for first-line treatment of RAS wild-type metastatic colorectal cancer

  This trial will test whether RPH-030 works like Vectibix when given with FOLFIRI as first-line treatment for people with metastatic colorectal cancer who have RAS wild-type tumors.

  Recruiting at 26 sites Phase 1 R-Pharm · Arkhangelsk and 25 other locations · NCT07543744

• JS212 combination treatments for metastatic colorectal cancer.

  This Phase 2 trial will test whether the experimental drug JS212, given with standard chemotherapy (capecitabine with or without bevacizumab or XELOX) and sometimes the immune drug JS207, is safe and active in adults with metastatic colorectal cancer who have not had prior systemic therapy for advanced disease.

  Recruiting Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07503756

• CEA-PRIT 2.0 for metastatic colorectal cancer

  This trial will test CEA-PRIT 2.0, a targeted pretargeted radioligand treatment using split antibodies and lead-based payloads, in people with metastatic microsatellite-stable colorectal cancer who have progressed on or cannot tolerate standard therapies.

  Recruiting at 5 sites Phase 1 Hoffmann-La Roche · Chicago, Illinois and 4 other locations · NCT07416552

• ASCEND-CRC: Testing personalized drug combinations for metastatic colorectal cancer

  We’re testing whether giving targeted drug combinations based on each patient’s tumor features can help control metastatic colorectal cancer.

  Recruiting Early Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07318389

• EMB-01 dosing for recurrent or metastatic left-sided colorectal cancer

  This trial tests two dosing schedules of EMB-01 in adults with recurrent or metastatic KRAS/BRAF wild-type left-sided colorectal cancer after first- or second-line treatment.

  Recruiting Phase 2 Shanghai EpimAb Biotherapeutics Co., Ltd. · Beijing and 1 other locations · NCT07314294

• Neoadjuvant immunotherapy with Dupilumab and Toripalimab for MSS colorectal cancer with resectable liver metastases

  This study tests a pre-surgery treatment combining dupilumab and toripalimab in adults with microsatellite-stable colorectal cancer that has liver metastases, to see if it’s safe and can lead to major tumor response.

  Recruiting Phase 1/2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07277322

• Second- and later-line palliative chemotherapy options for metastatic colorectal cancer.

  This study will see how different second- or later-line palliative chemotherapy treatments are used and what outcomes patients with metastatic colorectal cancer have after first-line chemotherapy stops working.

  Recruiting Boryung Pharmaceutical Co., Ltd · Seoul · NCT07263178

• First-in-human testing of repeated autologous TIL immunotherapy for metastatic colorectal and prostate cancer

  This trial tests whether repeated infusions of a patient’s own tumor-infiltrating lymphocytes (TILs) can persist longer in the blood and help people with metastatic colorectal or prostate cancer.

  Recruiting Phase 1/2 CuraCell TX AB · Frankfurt · NCT07255664

• BNT314 with BNT327 plus chemotherapy for advanced colorectal cancer

  This will test whether adding BNT314 and the immunotherapy BNT327 to standard chemotherapy helps people with metastatic, microsatellite-stable (MSS/pMMR) colorectal cancer.

  Recruiting at 14 sites Phase 1/2 BioNTech SE · New Haven, Connecticut and 13 other locations · NCT07079631

• Combining Glumetinib and Fruquintinib for Advanced Colorectal Cancer

  This study is testing whether combining two drugs, Glumetinib and Fruquintinib, can help people with advanced colorectal cancer that hasn't responded to previous treatments.

  Recruiting Phase 1/2 Tongji Hospital · Wuhan, Hubei · NCT06980532

• Evaluating a new treatment for advanced colorectal cancer

  This study is testing a new combination treatment for advanced colorectal cancer to see if it can help patients who haven't had success with other therapies.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT06979908

• Ivonescimab (anti-PD-1/VEGF bispecific) for previously treated metastatic colorectal cancer

  This trial will test whether ivonescimab can help control metastatic colorectal cancer in adults whose disease has progressed after prior treatments.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06959550

• Using precision medicine to choose chemotherapy for metastatic colorectal cancer

  This study is testing whether a new way to choose the best chemotherapy for people with metastatic colorectal cancer can help them live longer and feel better.

  Recruiting Phase 2 St. Olavs Hospital · Trondheim · NCT06907342

• Fruquintinib plus tislelizumab versus trifluridine/tipiracil plus bevacizumab for MSS/pMMR metastatic colorectal cancer without active liver metastases

  This trial tests whether combining fruquintinib with tislelizumab works better than trifluridine/tipiracil plus bevacizumab for adults with MSS/pMMR metastatic colorectal cancer who do not have active liver metastases.

  Recruiting at 15 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Linz and 22 other locations · NCT06856837

• Evaluating RBS2418 for advanced colorectal cancer

  This study is testing a new immune treatment called RBS2418 to see if it can help people with advanced colorectal cancer who haven't had success with other treatments.

  Recruiting at 8 sites Phase 2 Riboscience, LLC. · Newark, Delaware and 7 other locations · NCT06824064

• Evaluating a new treatment for metastatic colorectal cancer

  This study is testing a new drug combined with standard chemotherapy to see if it helps adults with metastatic colorectal cancer feel better and improve their condition.

  Recruiting at 82 sites Phase 2 AbbVie · Duarte, California and 81 other locations · NCT06820463

• Elovie (bevacizumab biosimilar) for metastatic colorectal cancer in Brazil

  This project will see if the biosimilar bevacizumab Elovie works well and is safe for adults in Brazil with unresectable stage IV metastatic colorectal cancer receiving first-line therapy.

  Recruiting at 14 sites Libbs Farmacêutica LTDA · Vitória, Espírito Santo and 13 other locations · NCT06808685

• Combination treatment for advanced colorectal cancer

  This study is testing a new combination of treatments for advanced colorectal cancer to see if it can help patients live longer and feel better.

  Recruiting Phase 1/2 Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center · Shenzhen, Guangdong · NCT06776757

• Treatment for patients with BRAFV600E mutant metastatic colorectal cancer

  This study looks at how well current treatments work for patients in China with advanced colorectal cancer that has a specific BRAFV600E mutation.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06749015

• Evaluating BBO-10203 for advanced solid tumors

  This study is testing a new treatment called BBO-10203, alone and with another drug, to see if it can help people with advanced solid tumors, including certain types of breast cancer.

  Recruiting at 43 sites Phase 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Duarte, California and 43 other locations · NCT06625775

• Combining radioembolization with FTD-TPI and bevacizumab for advanced colorectal cancer

  This study is testing if a new combination of a targeted radiation treatment and two medications can help people with advanced colorectal cancer who haven't responded to other treatments.

  Recruiting Phase 2 UMC Utrecht · Utrecht · NCT06563986

• Treatment with Enfortumab Vedotin for Advanced Colorectal and Liver Cancer

  This study is testing if a new drug called enfortumab vedotin can help adults with advanced colorectal or liver cancer who haven’t had success with other treatments.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06553885

• Combination treatment for advanced colorectal cancer

  This study is testing a new combination of treatments for people with advanced colorectal cancer who haven't had success with previous therapies to see if it helps them live longer without their cancer getting worse.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06551207

• Testing SSGJ-707 with chemotherapy for metastatic colorectal cancer

  This study is testing a new treatment called SSGJ-707 with chemotherapy to see if it helps people with metastatic colorectal cancer feel better compared to another treatment option.

  Recruiting Phase 2 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Shanghai, Shanghai Municipality · NCT06493760

• Combining Regorafenib with Metronomic Chemotherapy for Advanced Colorectal Cancer

  This study is testing if combining Regorafenib with a special type of chemotherapy and low-dose aspirin can help people with advanced colorectal cancer that hasn't improved with standard treatments.

  Recruiting at 11 sites Phase 2 Centre Hospitalier Universitaire de Besancon · Auxerre and 12 other locations · NCT06425133

• Combination treatment for advanced colorectal cancer with specific mutations

  This study is testing a combination of three drugs to see if they can help people with advanced colorectal cancer that has specific mutations after they've already tried other treatments.

  Recruiting at 2 sites Phase 1/2 M.D. Anderson Cancer Center · Boston, Massachusetts and 1 other locations · NCT06412198

• Combination therapy for metastatic colorectal cancer with BRAF-V600E mutation

  This study is testing a new combination of three drugs to see if it can help people with advanced colorectal cancer that has a specific mutation feel better and live longer after their previous treatments stopped working.

  Recruiting Phase 2 Vall d'Hebron Institute of Oncology · Barcelona · NCT06411600

• Using irinotecan liposomes with chemotherapy for advanced colorectal cancer

  This study is testing if a new way of giving irinotecan with chemotherapy can help people with advanced colorectal cancer live longer and feel better.

  Recruiting Phase 2 West China Hospital · Sichuan, Sichuan, Chengdu · NCT06341296

• Combination treatment for metastatic colorectal cancer

  This study is testing a combination of three drugs to see if it can help patients with certain types of metastatic colorectal cancer who have previously responded well to similar treatments.

  Recruiting Phase 2 Beijing Hospital · Beijing, Beijing Municipality · NCT06321081

• Comparing new treatments for metastatic colorectal cancer with a specific mutation

  This study is testing if a new combination of treatments can help people with a specific type of metastatic colorectal cancer feel better compared to standard treatments.

  Recruiting at 231 sites Phase 3 Amgen · Chandler, Arizona and 290 other locations · NCT06252649

• Testing a new chemotherapy for patients with DPD deficiency and metastatic cancer

  This study is testing a new chemotherapy drug for people with DPD deficiency and advanced colorectal or gastroesophageal cancer to see if it is safer and more effective than standard treatments.

  Recruiting at 3 sites Phase 2 Unicancer · Amiens and 20 other locations · NCT06245356

• Using Sacituzumab Govitecan for advanced colorectal cancer

  This study is testing a new drug called Sacituzumab Govitecan to see if it can help people with advanced colorectal cancer who haven't had success with other treatments.

  Recruiting Phase 2/3 University Hospital Heidelberg · Heidelberg, Baden-Wurttemberg · NCT06243393

• Treatment for metastatic colorectal cancer after previous therapies

  This study is testing if a new combination of medications can help people with metastatic colorectal cancer who haven't responded well to previous treatments.

  Recruiting Phase 2 Qilu Hospital of Shandong University · Jinan, Shandong · NCT06242067

• Combining Sotevtamab with FOLFOX for treating liver metastases in colorectal cancer

  This study is testing if combining a new drug called Sotevtamab with a standard chemotherapy treatment can help people with liver cancer from colorectal cancer get ready for surgery.

  Recruiting Phase 2 Alethia Biotherapeutics · Montreal, Quebec · NCT06225843

• Combination treatment for advanced colorectal cancer

  This study is testing a new combination treatment for people with advanced colorectal cancer to see if it helps them live longer without their cancer getting worse.

  Recruiting Phase 2 Fudan University · Shanghai · NCT06218810

• Using MRI to assess growth patterns in liver metastases from colorectal cancer

  This study is testing if a special type of MRI can help doctors see how colorectal cancer spreads in the liver to improve treatment plans for patients.

  Recruiting Shengjing Hospital · Shenyang, Liaoning · NCT06208397

• Exercise program for young patients with colorectal cancer undergoing chemotherapy

  This study is testing whether an exercise program can help young patients with colorectal cancer feel better during chemotherapy and improve their treatment results.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06202183

• FAPI PET/CT imaging to help diagnose CMS4 colorectal cancer

  A PET/CT imaging test using [18F]-ALF-FAPI-74 is being tried in adults with metastatic colorectal cancer who are undergoing surgery for liver metastases to see if the scan can reveal CMS4 subtype features.

  Recruiting UMC Utrecht · Utrecht, Utrecht · NCT06191120

• Combination immunotherapy for metastatic colorectal cancer

  This study is testing a new combination of four experimental cancer drugs to see if they can help people with metastatic colorectal cancer that usually doesn't respond to standard treatments.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06149481

• Combining ulixertinib with cetuximab and encorafenib for advanced colorectal cancer

  This study is testing a new combination of three drugs to see if they can safely help people with advanced colorectal cancer who haven't responded to other treatments.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT05985954

• Combining cetuximab and irinotecan for treating advanced colorectal cancer

  This study is testing if combining two drugs, cetuximab and irinotecan, can help patients with advanced colorectal cancer who haven't had success with other treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT05962502

• New treatment combination for advanced left-side colorectal cancer

  This study is testing a new combination of treatments for people with advanced left-side colorectal cancer to see if it helps them live longer without the cancer getting worse compared to the standard treatment.

  Recruiting at 3 sites Phase 2 Sun Yat-sen University · Foshan, Guangdong and 2 other locations · NCT05959356

• Evaluating the effects of radiotherapy on patients with oligometastatic cancer

  This study is testing how well Stereotactic Ablative Radiotherapy (SABR) works for people with oligometastatic cancer to see if it can help them live longer and feel better.

  Recruiting Institut Investigacio Sanitaria Pere Virgili · Albacete, Albacete and 20 other locations · NCT05933876

• Combining liposomal irinotecan, TAS102, and bevacizumab for advanced colorectal cancer

  This study is testing a new combination of three cancer drugs to see if it can help people with advanced colorectal cancer that hasn’t improved with other treatments.

  Recruiting Phase 2 University of Wisconsin, Madison · Madison, Wisconsin · NCT05854498

• Exploring blood biomarkers in colorectal cancer patients after liver surgery

  This study is testing if blood samples can help predict how well colorectal cancer patients do after surgery to remove liver tumors.

  Recruiting at 13 sites GERCOR - Multidisciplinary Oncology Cooperative Group · Besançon and 15 other locations · NCT05787197

• Understanding biomarkers in metastatic colorectal cancer treatment

  This study is trying to see how cancer changes during treatment in people with metastatic colorectal cancer and whether certain genetic markers can help tailor better treatment options for them.

  Recruiting at 2 sites Region Skane · Lund, Skåne County and 1 other locations · NCT05755672

• Personalized treatment for metastatic colorectal cancer

  This study tests a personalized cancer treatment for people with metastatic colorectal cancer who have already tried standard chemotherapy to see if it can improve their outcomes.

  Recruiting Phase 2 Oslo University Hospital · Oslo · NCT05725200

• Collecting data from patients with BRAFV600E-mutated metastatic colorectal cancer

  This study is collecting information and samples from patients with a specific type of metastatic colorectal cancer to see how well different treatments work and what factors affect their outcomes.

  Recruiting at 27 sites Unicancer · Avignon and 44 other locations · NCT05639413

• Monitoring targeted therapy drugs in patients with advanced digestive cancers

  This study is testing how to best monitor and adjust the doses of targeted therapy drugs for people with advanced digestive cancers to make sure they are safe and effective.

  Recruiting at 19 sites Unicancer · Amiens and 28 other locations · NCT05443087

• Combining nivolumab and ipilimumab for advanced colorectal cancer resistant to anti-PD1 treatment

  This study is testing if combining two cancer drugs, nivolumab and ipilimumab, can help people with advanced colorectal cancer that hasn't responded to other treatments.

  Recruiting at 9 sites Phase 2 GERCOR - Multidisciplinary Oncology Cooperative Group · Besançon and 8 other locations · NCT05310643

• Using the Oncogramme® Device to Choose Treatment for Metastatic Colorectal Cancer

  This study tests if using the Oncogramme® device to choose chemotherapy can help people with metastatic colorectal cancer get better treatment results compared to standard methods.

  Recruiting Oncomedics · Marseille · NCT05299840

• Evaluating BEY1107 with Capecitabine for metastatic colorectal cancer

  This study is testing a new treatment called BEY1107 combined with capecitabine to see if it helps people with metastatic colorectal cancer who haven't had success with standard treatments.

  Recruiting Phase 1/2 BeyondBio Inc. · Seoul, Jongro-go · NCT05093907

• Comparing two treatments for metastatic colorectal cancer

  This study is testing which combination of treatments works better for people with metastatic colorectal cancer: one with panitumumab or the other with bevacizumab.

  Recruiting Phase 2 Charite University, Berlin, Germany · Berlin · NCT05007132

• Evaluating targeted therapies for metastatic colorectal cancer

  This study is testing if targeted therapies and immunotherapy can help people with metastatic colorectal cancer who have certain biomarkers in their tumors.

  Recruiting at 56 sites Phase 1 Hoffmann-La Roche · Birmingham, Alabama and 83 other locations · NCT04929223

• FOLFOXIRI plus temozolomide and bevacizumab for MGMT‑silenced, microsatellite‑stable metastatic colorectal cancer

  This trial tests whether adding temozolomide to a FOLFOXIRI plus bevacizumab regimen helps people whose metastatic colorectal cancer is MGMT‑silenced and microsatellite‑stable.

  Recruiting at 3 sites Phase 1/2 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan, Milan and 2 other locations · NCT04689347

• Treatment of advanced or metastatic solid tumors with ART0380

  This study is testing a new drug called ART0380 to see if it can safely help people with advanced solid tumors that have specific DNA repair issues, either on its own or with other chemotherapy drugs.

  Recruiting at 62 sites Phase 1/2 Artios Pharma Ltd · Birmingham, Alabama and 87 other locations · NCT04657068

• Evaluating a new treatment for metastatic colorectal cancer

  This study is testing a new treatment combining Serplulimab, Bevacizumab, and chemotherapy to see if it helps people with advanced colorectal cancer feel better and live longer.

  Recruiting at 4 sites Phase 2/3 Shanghai Henlius Biotech · Guangzhou, Guangdong and 4 other locations · NCT04547166

• Treatment to make inoperable liver cancer operable

  This study is testing a combination treatment to see if it can make liver cancer that can't currently be operated on eligible for surgery in patients with metastatic colorectal cancer.

  Recruiting Phase 2 University of Saskatchewan · Regina, Saskatchewan · NCT03401294

• Immunotherapy using tumor-infiltrating lymphocytes for metastatic cancer

  This study is testing a new immunotherapy that uses special white blood cells from patients' tumors to see if it can help people with metastatic cancers get better, especially when combined with another treatment called pembrolizumab.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT01174121

NIH-funded research (19)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Population-based view of patient-reported outcomes in adults with metastatic colorectal cancer

  This grant funds a long-term study to understand experiences and quality of life for adults living with metastatic colorectal cancer.

  NIH research Georgetown University · Washington, United States · NIH-11395424

• Nanodelivery of FP polymers to improve treatment of metastatic colorectal cancer

  A new nanoscale therapy called CF10 is being developed to deliver a chemotherapy drug more directly to metastatic colorectal cancer, aiming for better tumor targeting and fewer side effects.

  NIH research Wake Forest University Health Sciences · Winston-Salem, United States · NIH-11365062

• How metastatic colorectal cancer weakens muscles and bones

  This research looks at how metastatic colorectal cancer and a hormone called FGF21 cause muscle and bone wasting in people with advanced colorectal cancer.

  NIH research Indiana University Indianapolis · Indianapolis, United States · NIH-11330251

• Nanoscale polymers delivering patient-specific cancer vaccines for metastatic colorectal cancer

  A new therapy uses tiny, designer particles to carry patient-specific cancer antigens to tumors in people with advanced colorectal cancer.

  NIH research University of Chicago · Chicago, United States · NIH-11328849

• Targeted nanoparticles combining chemotherapy and immune stimulation for advanced colon cancer

  Targeted nanoparticles that deliver a two-drug chemotherapy combo plus immune-activating components are being developed to help people with metastatic colorectal (colon) cancer that usually does not respond to current immunotherapy.

  NIH research University of Chicago · Chicago, United States · NIH-11294219

• Symptoms and quality of life in adults living with metastatic colorectal cancer

  Researchers will follow adults with metastatic colorectal cancer over time to learn what symptoms and quality-of-life issues they experience during treatment and survivorship.

  NIH research Georgetown University · Washington, United States · NIH-11162244

• miR-15a microRNA therapy for advanced metastatic colorectal cancer

  A new treatment using a small RNA called miR-15a is being developed to help people, including Veterans, with advanced metastatic colorectal cancer that is resistant to standard chemotherapy.

  NIH research Northport VA Medical Center · Northport, United States · NIH-11130922

• Improving advanced colon cancer treatment with tiny drug carriers

  This project explores new ways to deliver a promising drug, CF10, using tiny particles to better treat advanced colon cancer.

  NIH research Wake Forest University Health Sciences · Winston-Salem, United States · NIH-11124810

• Understanding the impact of metastatic colorectal cancer on muscle and bone health

  This study is looking at how advanced colorectal cancer causes weight loss and muscle weakness, and it aims to find out if a hormone called FGF21 plays a role in this, so we can discover new ways to help patients feel better and maintain their strength.

  NIH research Indiana University Indianapolis · Indianapolis, United States · NIH-11104717

• Using nanoscale polymers to improve treatment for metastatic colorectal cancer

  This study is looking at new tiny materials that can help make cancer treatments work better for people with metastatic colorectal cancer, especially those whose tumors don’t respond well to current therapies, by creating personalized vaccines that boost the immune system to fight the cancer more effectively.

  NIH research University of Chicago · Chicago, United States · NIH-11086798

• Using smart nanoparticles to deliver a natural cancer-fighting drug for metastatic colorectal cancer.

  This study is testing a new way to deliver a natural anti-cancer drug directly to metastatic colorectal cancer cells using tiny particles, which could make the treatment work better and cause fewer side effects for patients with advanced CRC.

  NIH research University of South Dakota · Vermillion, United States · NIH-11077358

• Identifying new targets for treating metastatic colorectal cancer

  This study is looking for special markers in advanced colorectal cancer that could help create better treatments using CAR T cell therapy, aiming to find targets that are unique to cancer cells and not found in healthy tissues, so patients can have more effective options for their care.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11035804

• New treatment approach for metastatic colorectal cancer using nanoscale polymers

  This study is testing a new treatment for metastatic colorectal cancer that uses tiny particles to help your immune system better recognize and fight tumors, especially if your cancer hasn't responded to other therapies.

  NIH research University of Chicago · Chicago, United States · NIH-11035186

• Understanding the experiences of adults living with metastatic colorectal cancer

  This study is looking to understand how adults with metastatic colorectal cancer feel and what they need while going through treatment, so we can create better support for them.

  NIH research Georgetown University · Washington, United States · NIH-10931430

• Understanding how changes in tissue stiffness affect colorectal cancer progression

  This study is looking at how the stiffness of the surrounding tissue affects cancer cell behavior in colorectal cancer, using a special gel that can change its firmness with light, to help find better ways to treat the disease.

  NIH research University of Washington · Seattle, United States · NIH-10889787

• Developing new treatments for advanced colorectal cancer using miRNA.

  This study is looking at how a tiny molecule called miR-15a affects colorectal cancer and hopes to develop a new treatment that works like it, especially for Veterans with advanced cancer who haven't had success with regular chemotherapy.

  NIH research Northport VA Medical Center · Northport, United States · NIH-10881635

• Improving treatment for metastatic colorectal cancer using nanotechnology

  This study is looking at a new way to make chemotherapy work better for people with metastatic colorectal cancer by using a special tiny delivery system to send the drug 5-fluorouracil right to the tumor, which could help reduce side effects and improve treatment results.

  NIH research Wake Forest University Health Sciences · Winston-Salem, United States · NIH-10870118

• Engineering bacteria to treat metastatic colorectal cancer

  This study is exploring how specially designed bacteria can help treat metastatic colorectal cancer by making them smart enough to find and attack cancer cells, and it’s aimed at improving treatment options for patients like you.

  NIH research Columbia Univ New York Morningside · New York, United States · NIH-10733437

• Creating new drugs to treat metastatic colorectal cancer

  This study is working on a new type of medicine that targets a specific protein to help treat metastatic colorectal cancer, which currently has limited treatment options, and they’re testing a promising compound that could be taken as a pill to see how well it works.

  NIH research Hb Therapeutics, INC. · Indianapolis, UNITED STATES · NIH-10651880

Related topics

Quick answers

How many Metastatic Colorectal Cancer clinical trials are recruiting right now?

66, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 41 countries. The most sites are in China (20 trials), United States (18 trials), France (12 trials), Spain (9 trials), Germany (8 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 30, Phase 1/2: 10, Phase 1: 6, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →